Chemistry: analytical and immunological testing – Peptide – protein or amino acid
Reexamination Certificate
2011-08-23
2011-08-23
Gakh, Yelena G. (Department: 1777)
Chemistry: analytical and immunological testing
Peptide, protein or amino acid
C422S068100
Reexamination Certificate
active
08003396
ABSTRACT:
The present invention relates to a method of diagnosing if a subject which has suffered from an acute myocardial infarction is also suffering from a pre-existing myocardial dysfunction, the method comprising a) determining the amount of a natriuretic peptide in a sample of the subject; b) determining the amount of a cardiac troponin in a sample of the subject; c) calculating the ratio (natriuretic peptide/cardiac troponin); and d) diagnosing if the elevated natriuretic peptide level is related to a preexisting myocardial dysfunction or if the elevated level is caused by the acute myocardial infarction, based on the ratio calculated in step c). The method allows determining whether the individual has suffered from a myocardial dysfunction, in particular heart failure, before the myocardial infarction has occurred.
REFERENCES:
patent: 5744305 (1998-04-01), Fodor et al.
patent: 0648228 (1998-11-01), None
patent: 1837659 (2007-09-01), None
patent: 02/083913 (2002-10-01), None
patent: 2002/089657 (2002-11-01), None
patent: WO-2006/131529 (2006-12-01), None
Mega, J. L. et al. “B-Type Natriuretic Peptide at Presentation and Prognosis in Patients With ST-Segment Elevation Myocardial Infarction,” Journal of the American College of Cardiology, 2004, 44, 335-339.
International Search Report issued Jan. 21, 2009 in PCT Application No. PCT/EP2008/063518.
International Preliminary Report on Patentability issued Apr. 13, 2010 in PCT Application No. PCT/EP2008/063518.
Anderson, Page A. W. et al., Molecular Basis of Human Cardiac Troponin T Isoforms Expressed in the Developing, Adult, and Failing Heart, Circulation Research, 1995, pp. 681-686, vol. 76, No. 4.
Beck-Da-Silva, Luis et al., Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm, Canadian Journal of Cardiology, Oct. 2004, pp. 1245-1248, vol. 20, No. 12.
Bonow, Robert O., New Insights Into the Cardiac Natriuretic Peptides, Circulation, 1996, pp. 1946-1950, vol. 93.
Fonarow, Gregg C. et al., Combining Natriuretic Peptides and Necrosis Markers in Determining Prognosis in Heart Failure, Reviews in Cardiovascular Medicine, 2003, pp. S20-S28, vol. 4, Supplement No. 4.
Ferrieres, Gaelle et al., Human cardiac troponin I: precise identification of antigenic epitopes and prediction of secondary structure, Clinical Chemistry, 1998, pp. 487-493, vol. 44, No. 3.
Joint European Society of Cardiology/American College of Cardiology Committee, Myocardial Infarction Redefined—A Consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of myocardial Infarction, Journal of the American College of Cardiology, 2000, pp. 959-969, vol. 36, No. 3.
Karl, J. et al., Development of a novel, N-Terminal-proBNP (NT-proBNP) assay with a low detection limit, Scandianavian Journal of Clinical Laboratory Investigation, 1999, pp. 177-181, vol. 59, Supplement 230.
Latini, Roberto et al., Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients with Stable Chronic Heart Failure, Circulation, 2007, pp. 1242-1249, vol. 116.
Mueller, Thomas et al., Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples, Clinical Chem Lab Med, 2004, pp. 942-944, vol. 42.
Nolan, James P. and Sklar, Larry A., Suspension array techonology: evolution of the flat-array paradigm, Trends in Biotechnology, Jan. 2002, pp. 9-12, vol. 20, No. 1.
Smith, M. W. et al., Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase, Journal of endocrinology, 2000, pp. 239-246, vol. 167.
Taniguchi, Ryoji et al., Combined Measurements of Cardiac Troponin T and N-Terminal Pro-Brain Natriuretic Peptide in Patients With Heart Failure, Circulation Journal, Dec. 2004, pp. 1160-1164, vol. 68.
Taniguchi, Ryoji et al., Measurments of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies, Heart Vessels, 2006, pp. 344-349, vol. 21.
Tsuchida, Keizo and Tanabe, Kazuhiko, Influence of Paroxysmal Atrial Fibrillation Attack on Brain Natriuretic Peptide Secretion, Journal of Cardiology, Jul. 2004, pp. 1-11, vol. 44, No. 1.
Wu, Alan H. B. et al., Analytical and Clinical Evaluation of the Bayer ADVIA Centaur automated B-Type Natriuretic Peptide Assay in Patients with Heart Failure: A Multisite Study, clinical Chemistry, 2004, pp. 867-873, vol. 50, No. 5.
Yeo, Kiang-Teck J. et al., Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay, Clinica Chemica Acta, 2003, pp. 107-115, vol. 338.
Hess Georg
Horsch Andrea
Zdunek Dietmar
Adams Michelle
Gakh Yelena G.
Roche Diagnostics Operations Inc.
Roche Diagnostics Operations Inc.
LandOfFree
NT-proBNP/troponin ratio for assessing myocardial dysfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NT-proBNP/troponin ratio for assessing myocardial dysfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NT-proBNP/troponin ratio for assessing myocardial dysfunction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2688288